These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36531687)

  • 1. Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8
    Di Trani CA; Cirella A; Arrizabalaga L; Bella Á; Fernandez-Sendin M; Russo-Cabrera JS; Gomar C; Olivera I; Bolaños E; González-Gomariz J; Álvarez M; Etxeberria I; Palencia B; Teijeira Á; Melero I; Berraondo P; Aranda F
    Oncoimmunology; 2023; 12(1):2147317. PubMed ID: 36531687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.
    Bella Á; Arrizabalaga L; Di Trani CA; Gonzalez-Gomariz J; Gomar C; Russo-Cabrera JS; Olivera I; Cirella A; Fernandez-Sendin M; Alvarez M; Teijeira A; Atay C; Medina-Echeverz J; Hinterberger M; Hochrein H; Melero I; Berraondo P; Aranda F
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.
    Galvan DL; O'Neil RT; Foster AE; Huye L; Bear A; Rooney CM; Wilson MH
    PLoS One; 2015; 10(10):e0140744. PubMed ID: 26473608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8
    Etxeberria I; Bolaños E; Quetglas JI; Gros A; Villanueva A; Palomero J; Sánchez-Paulete AR; Piulats JM; Matias-Guiu X; Olivera I; Ochoa MC; Labiano S; Garasa S; Rodriguez I; Vidal A; Mancheño U; Hervás-Stubbs S; Azpilikueta A; Otano I; Aznar MA; Sanmamed MF; Inogés S; Berraondo P; Teijeira Á; Melero I
    Cancer Cell; 2019 Dec; 36(6):613-629.e7. PubMed ID: 31761658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
    Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
    J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.
    Jiang H; Shin DH; Yi Y; Fan X; Gumin J; He J; Gillard AG; Lang FF; Gomez-Manzano C; Fueyo J
    Cancer Res Commun; 2023 Jun; 3(6):1118-1131. PubMed ID: 37379361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
    Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
    J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.
    Miller AM; Bahmanof M; Zehn D; Cohen EEW; Schoenberger SP
    Cancer Immunol Res; 2019 Jan; 7(1):40-49. PubMed ID: 30482746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen).
    Goldberg J; Shrikant P; Mescher MF
    J Immunol; 2003 Jan; 170(1):228-35. PubMed ID: 12496404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation.
    Kezuka T; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1803-11. PubMed ID: 10845601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
    Tähtinen S; Grönberg-Vähä-Koskela S; Lumen D; Merisalo-Soikkeli M; Siurala M; Airaksinen AJ; Vähä-Koskela M; Hemminki A
    Cancer Immunol Res; 2015 Aug; 3(8):915-25. PubMed ID: 25977260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
    Kerkar SP; Muranski P; Kaiser A; Boni A; Sanchez-Perez L; Yu Z; Palmer DC; Reger RN; Borman ZA; Zhang L; Morgan RA; Gattinoni L; Rosenberg SA; Trinchieri G; Restifo NP
    Cancer Res; 2010 Sep; 70(17):6725-34. PubMed ID: 20647327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal 3 availability limits the CD8 T cell response to a solid tumor.
    Curtsinger JM; Gerner MY; Lins DC; Mescher MF
    J Immunol; 2007 Jun; 178(11):6752-60. PubMed ID: 17513722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
    Goding SR; Yu S; Bailey LM; Lotze MT; Basse PH
    Clin Immunol; 2017 Apr; 177():76-86. PubMed ID: 27377534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy.
    Olivera I; Bolaños E; Gonzalez-Gomariz J; Hervas-Stubbs S; Mariño KV; Luri-Rey C; Etxeberria I; Cirella A; Egea J; Glez-Vaz J; Garasa S; Alvarez M; Eguren-Santamaria I; Guedan S; Sanmamed MF; Berraondo P; Rabinovich GA; Teijeira A; Melero I
    Cell Rep Med; 2023 Mar; 4(3):100978. PubMed ID: 36933554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.